Background illustration for clinical trials search

Multiple Sclerosis Clinical Trials

Browse 937 multiple sclerosis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities

for
Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease,
Location: Baltimore MD
Sponsor: LifeBridge Health

Sex: All

Age: 18+

Code: NCT06168968

Recruiting

Team Approach to Polypharmacy Evaluation and Reduction (Pharmacy)

for
Multi-morbidity, Medication Therapy Management, Polypharmacy
Location: Hamilton
Sponsor: McMaster University

Sex: All

Age: 70+

Code: NCT03557944

Recruiting

Losartan to Improve Outcomes After Multi-ligament Knee Injury

for
Multi-ligament Knee Injury
Location: Foxborough MA
Sponsor: Brigham and Women's Hospital

Sex: All

Age: 18 - 40

Code: NCT06933706

Phase2, Recruiting

Using Antibiotics Wisely - An Antimicrobial Stewardship Program

for
Multi-Drug Resistant Organisms, Late-Onset Sepsis, Neonatal,
Location: Edmonton
Sponsor: University of British Columbia

Sex: All

Age: 0

Code: NCT04388293

Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

for
Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 0+

Code: NCT07382739

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
New

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

for
AL Amyloidosis, Multiple Myeloma
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07850284

Recruiting
New

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: New York NY, Houston TX, Irvine CA, Duarte CA
Sponsor: Fortvita Biologics (USA)Inc.

Sex: All

Age: 18+

Code: NCT07336472

Phase1, Phase2, Recruiting
New

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

for
Multiple Myeloma
Location: Hackensack NJ, Washington D.C. DC
Sponsor: Hackensack Meridian Health

Sex: All

Age: 18+

Code: NCT04661137

Phase2, Recruiting
New

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Ottawa IL, Bloomington IL, Decatur IL, Peru IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06948084

Phase2, Recruiting
New

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

for
Myeloma Multiple
Location: Anchorage AK
Sponsor: Eastern Cooperative Oncology Group

Sex: All

Age: 18+

Code: NCT07085728

Phase2, Recruiting
New

A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Rochester MN
Sponsor: Vyriad, Inc.

Sex: All

Age: 18+

Code: NCT07802717

Phase1, Recruiting

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

for
Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms,
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05093335

Early_phase1, Recruiting

Elranatamab in R/R Multiple Myeloma

for
Refractory Multiple Myeloma, Relapse Multiple Myeloma,
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT06138275

Phase2, Recruiting

Transcutaneous Spinal Cord Stimulation Home Study

for
Spinal Cord Injuries,
Location: Vancouver
Sponsor: Michael Berger

Sex: All

Age: 19 - 70

Code: NCT06838637

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma, Myeloma, Myeloma Multiple
Location: Boston MA, New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: K36 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05651932

Phase1, Recruiting

[18F]F-DOPA Imaging in Patients With Autonomic Failure

for
Autonomic Failure, Pure Autonomic Failure, Parkinson Disease,
Location: Nashville TN
Sponsor: Daniel Claassen

Sex: All

Age: 18+

Code: NCT04246437

Phase1, Recruiting

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

for
Recurrent Multiple Myeloma
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06785415

Phase1, Phase2, Recruiting

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

for
Multiple Myeloma
Location: Miami FL, Irvine CA
Sponsor: Hoag Memorial Hospital Presbyterian

Sex: All

Age: 21+

Code: NCT04814615

Phase2, Recruiting

The Ambient Light Multiple Myeloma Study

for
Multiple Myeloma
Location: New York NY
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 21+

Code: NCT05737732

Recruiting

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

for
Multiple Myeloma
Location: Ottawa
Sponsor: Ottawa Hospital Research Institute

Sex: All

Age: 18 - 60

Code: NCT00800059

Phase1, Phase2, Recruiting

What is multiple sclerosis?

In MS, the immune system attacks myelin, the insulation around nerve fibers in the brain and spinal cord. Damaged spots, called lesions, slow or block nerve signals, which is why symptoms range from fatigue and numbness to vision problems and trouble walking. Symptoms and pace differ so much between people that MS is often called a disease with a thousand faces. It is not contagious, and it is not directly inherited. Worldwide about 2.9 million people live with MS, someone is diagnosed roughly every five minutes, and the average age at diagnosis is 32.

Research in this field carries one of the most striking findings in modern medicine: a 2022 study of more than 10 million US military members found that infection with the Epstein Barr virus, the common virus behind mononucleosis, raises MS risk 32 times, making it the leading suspected cause. Meanwhile treatment keeps expanding, with more than 20 approved disease modifying therapies, though the progressive forms still have almost none.

The types of MS, and why they matter for trials

Types of multiple sclerosis clinical trials

Who can participate in MS trials?

Do MS trial participants get paid?

How to enroll in a clinical trial for multiple sclerosis